Mercedes Jacobson, MD
Neurology · Philadelphia, PANPI 1770571754
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,684 of the $2,657 with a category attached, or 63.4%. 12 manufacturers reported payments, led by Livanova USA, Inc. at 47.9% of the total. Reporting peaked in 2022 at $1,350 and has fallen 87.1% since, to $174 in 2025.
Across 49 payments — averaging $54.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$1K
- UCB, Inc.$571
- Jazz Pharmaceuticals Inc.$193
- Sunovion Pharmaceuticals Inc.$117
- Neurelis, Inc.$110
- SK Life Science, Inc.$84
- plus $308 from 6 others
Across 42 payments — averaging $4181.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$61K
- UCB, Inc.$34K
- Immedica Pharma US, Inc.$27K
- Eli Lilly$26K
- Sunovion Pharmaceuticals Inc.$23K
- SK Life Science, Inc.$5K
What the payments were for
- Travel & lodging$92135%
- Food & beverage$1,68463%
- Education$532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 4 | $1,274 |
| UCB, Inc. | 13 | $571 |
| Jazz Pharmaceuticals Inc. | 2 | $193 |
| Sunovion Pharmaceuticals Inc. | 8 | $117 |
| Neurelis, Inc. | 5 | $110 |
| SK Life Science, Inc. | 4 | $84 |
| Sumitomo Pharma America, Inc. | 5 | $80 |
| AbbVie | 2 | $55 |
| AstraZeneca(2 entities) | 2 | $52 |
| Neuropace, Inc. | 1 | $43 |
| Catalyst Pharmaceuticals, Inc. | 2 | $39 |
| Ceribell, Inc. | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,231
- Epidiolex$147
How this compares
$2,657 in reported general payments places this provider in the 65th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 262 | $494,568 |
| EpidiolexCannabidiol (Cbd) | 33 | $200,852 |
| FycompaPerampanel | 36 | $45,482 |
| XcopriCenobamate | 39 | $45,048 |
| NayzilamMidazolam | 38 | $35,443 |
| Lacosamide | 233 | $31,508 |
| Rufinamide | 18 | $26,214 |
| ValtocoDiazepam | 26 | $17,597 |
| Topiramate ErTopiramate | 11 | $12,818 |
| Emgality PenGalcanezumab-Gnlm | 15 | $10,354 |
| Clobazam | 92 | $9,111 |
| Levetiracetam | 226 | $7,897 |
| Carbamazepine ErCarbamazepine | 72 | $7,720 |
| Lamotrigine | 160 | $6,429 |
| Oxcarbazepine | 70 | $4,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Nayzilam | $571 | $530,010300 claims |
| SK Life Science, Inc.Xcopri | $84 | $45,04839 claims |
| Neurelis, Inc.Valtoco | $110 | $17,59726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Stephanie Nahas-GeigerPhiladelphia$786K
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Joseph BergerPhiladelphia$384K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.